Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast versus etanercept versus placebo in moderate to severe plaque psoriasis
NL-OMON44059Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Oct 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Apremilast, Etanercept and Placebo (3 arms). Primary endpoint: PASI-75 at Week 16. Started Oct 2012; status: active, not recruiting.
02
Drugs
apremilastetanercept
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NL-OMON44059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44059.